Global Patent Index - EP 1890729 A2

EP 1890729 A2 20080227 - USE OF CAROTENOIDS AND/OR CAROTENOID DERIVATIVES/ANALOGS FOR REDUCTION/INHIBITION OF CERTAIN NEGATIVE EFFECTS OF COX INHIBITORS

Title (en)

USE OF CAROTENOIDS AND/OR CAROTENOID DERIVATIVES/ANALOGS FOR REDUCTION/INHIBITION OF CERTAIN NEGATIVE EFFECTS OF COX INHIBITORS

Title (de)

VERWENDUNG VON KAROTENOIDEN UND/ODER KAROTENOIDDERIVATEN/-ANALOGA ZUR VERRINGERUNG/HEMMUNG GEWISSER NEGATIVER WIRKUNGEN VON COX-HEMMERN

Title (fr)

UTILISATION DE CAROTENOIDES ET/OU DE DERIVES/ANALOGUES DE CAROTENOIDES DANS LA REDUCTION/INHIBITION DE CERTAINS EFFETS NEGATIFS DES INHIBITEURS DE COX

Publication

EP 1890729 A2 20080227 (EN)

Application

EP 06758837 A 20060502

Priority

  • US 2006016590 W 20060502
  • US 67595905 P 20050502
  • US 69971705 P 20050715
  • US 71845005 P 20050919

Abstract (en)

[origin: WO2006119168A2] Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.

IPC 8 full level

A61K 45/06 (2006.01); A61K 31/196 (2006.01); A61K 31/415 (2006.01); A61K 31/522 (2006.01); A61P 29/00 (2006.01); A61P 43/00 (2006.01)

CPC (source: EP)

A61K 31/015 (2013.01); A61K 31/196 (2013.01); A61K 31/415 (2013.01); A61K 31/522 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61P 43/00 (2018.01)

C-Set (source: EP)

  1. A61K 31/015 + A61K 2300/00
  2. A61K 31/196 + A61K 2300/00
  3. A61K 31/415 + A61K 2300/00
  4. A61K 31/522 + A61K 2300/00

Citation (search report)

See references of WO 2006119168A3

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006119168 A2 20061109; WO 2006119168 A3 20070125; CA 2613169 A1 20061109; EP 1890729 A2 20080227

DOCDB simple family (application)

US 2006016590 W 20060502; CA 2613169 A 20060502; EP 06758837 A 20060502